The move paints a more specific outline of what Sandoz’s strategic ambitions are more than a year since it spun off from Novartis.
The biosimilars maker likely faces a minimum six-month delay before a new decision date on Stelara.
Makers of biosimilars must still work within a health care system in which basic economics rarely seems to hold sway.
Copycat versions of branded cancer drug Herceptin led to lower biologic prices, yet the real test for biosimilars lies ahead.
For biosimilars, the average sales price has decreased at a negative compound annual growth rate of -9% to -24%.
While the average brand name copay is more than $56, the average generic copay is just around $6.
Drugs are still being approved and reports are still churning out, all while the FDA battles the COVID-19 outbreak.
The FDA and FTC want to ensure companies don’t use anticompetitive practices to squash the biosimilar market.
A recent IQVIA report breaks down global medicine spending and eyes what lies ahead.
A report from the IQVIA Institute for Human Data Science identified areas to watch through 2023.
MM+M Transform: The Patient, Provider and Payer Engagement Matrix provides the most in-depth look at the marketing and technology trends likely to influence the industry’s growth over the next year.
Get the most out of
Register for free and enjoy unlimited access to: